See more : Pacifico Acquisition Corp. (PAFO) Income Statement Analysis – Financial Results
Complete financial analysis of Cyclacel Pharmaceuticals, Inc. (CYCCP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cyclacel Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Wilh. Wilhelmsen Holding ASA (WWI.OL) Income Statement Analysis – Financial Results
- Knowles Corporation (KN) Income Statement Analysis – Financial Results
- Top Wealth Group Holding Limited Ordinary Shares (TWG) Income Statement Analysis – Financial Results
- Cygnus Oil & Gas Corp. (CYNS) Income Statement Analysis – Financial Results
- Netcompany Group A/S (NETC.CO) Income Statement Analysis – Financial Results
Cyclacel Pharmaceuticals, Inc. (CYCCP)
About Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 420.00K | 0.00 | 0.00 | 0.00 | 0.00 | 150.00K | 0.00 | 843.00K | 1.94M | 1.73M | 1.08M | 69.00K | 699.00K | 686.00K | 911.00K | 877.00K | 129.00K | 387.00K | 813.00K | 62.00K | 170.00K | 0.00 | 30.00K | 98.00K |
| Cost of Revenue | 0.00 | 32.00K | 43.00K | 20.00K | 20.00K | 4.33M | 32.00K | 9.48M | 12.38M | 18.28M | 11.28M | 6.59M | 360.00K | 418.00K | 545.00K | 429.00K | 19.57M | 21.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 420.00K | -32.00K | -43.00K | -20.00K | -20.00K | -4.18M | -32.00K | -8.63M | -10.44M | -16.54M | -10.19M | -6.52M | 339.00K | 268.00K | 366.00K | 448.00K | -19.44M | -20.82M | 813.00K | 62.00K | 170.00K | 0.00 | 30.00K | 98.00K |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,784.67% | 0.00% | -1,024.20% | -536.93% | -954.04% | -940.31% | -9,453.62% | 48.50% | 39.07% | 40.18% | 51.08% | -15,069.77% | -5,379.33% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 19.16M | 20.27M | 15.48M | 4.76M | 4.66M | 4.33M | 4.24M | 9.48M | 12.38M | 18.28M | 11.28M | 6.59M | 9.21M | 6.41M | 9.77M | 18.87M | 10.00K | 231.00K | 13.77M | 19.70M | 13.69M | 14.66M | 14.70M | 11.26M |
| General & Administrative | 6.72M | 7.38M | 7.46M | 5.88M | 5.02M | 5.37M | 5.25M | 5.52M | 5.73M | 5.89M | 7.78M | 8.58M | 7.52M | 10.12M | 8.54M | 15.35M | 11.54M | 12.32M | 9.67M | 6.88M | 4.32M | 0.00 | 5.20M | 2.40M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.72M | 7.38M | 7.46M | 5.88M | 5.02M | 5.37M | 5.25M | 5.52M | 5.75M | 5.89M | 7.78M | 8.58M | 7.52M | 10.12M | 8.54M | 15.35M | 11.54M | 12.32M | 9.67M | 6.88M | 4.32M | 4.98M | 5.20M | 2.40M |
| Other Expenses | 0.00 | 1.30M | 144.00K | 891.00K | 231.00K | 682.00K | 949.00K | 0.00 | 12.13K | 0.00 | 0.00 | 0.00 | 360.00K | 6.73M | 911.00K | 8.85M | 21.11M | 0.00 | 7.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 25.87M | 27.66M | 22.94M | 10.64M | 9.68M | 9.70M | 9.49M | 14.99M | 18.13M | 24.17M | 19.06M | 15.17M | 16.73M | 16.53M | 18.30M | 34.22M | 11.54M | 12.32M | 30.50M | 26.57M | 18.01M | 19.64M | 19.91M | 13.66M |
| Cost & Expenses | 25.87M | 27.66M | 22.94M | 10.64M | 9.68M | 9.70M | 9.49M | 14.99M | 18.13M | 24.17M | 19.06M | 15.17M | 17.09M | 16.95M | 18.85M | 34.65M | 31.11M | 33.52M | 30.50M | 26.57M | 18.01M | 19.64M | 19.91M | 13.66M |
| Interest Income | 266.00K | 210.00K | 16.00K | 42.00K | 224.00K | 331.00K | 118.00K | 37.00K | 9.00K | 6.00K | 13.00K | 22.00K | 45.00K | 37.00K | 102.00K | 1.38M | 3.55M | 2.33M | 960.00K | 421.00K | 149.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 43.00K | 177.00K | 318.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 31.00K | 32.00K | 43.00K | 20.00K | 20.00K | 29.00K | 32.00K | 133.00K | 210.00K | 174.00K | 70.00K | 60.00K | 241.00K | 457.00K | 668.00K | 1.86M | 299.00K | 1.10M | 1.55M | 1.31M | 929.00K | 0.00 | 0.00 | -621.00K |
| EBITDA | -25.42M | -27.62M | -22.69M | -10.62M | -9.66M | -9.52M | -9.46M | -14.02M | -15.96M | -22.26M | -17.90M | -15.05M | -15.57M | -16.18M | -19.67M | -39.96M | -24.75M | -30.13M | -19.45M | -24.48M | -16.91M | -19.64M | -19.88M | -14.18M |
| EBITDA Ratio | -6,052.86% | 0.00% | 0.00% | 0.00% | 0.00% | -6,305.33% | 0.00% | -1,718.74% | -817.13% | -1,281.37% | -1,656.92% | -21,782.61% | -2,303.58% | -2,299.13% | -1,957.85% | -3,481.53% | -24,993.80% | -8,165.89% | -2,551.54% | -39,482.26% | -9,945.29% | 0.00% | -66,250.00% | -14,472.45% |
| Operating Income | -25.45M | -27.66M | -22.94M | -10.64M | -9.68M | -9.55M | -9.49M | -14.15M | -16.17M | -22.44M | -17.97M | -15.10M | -16.39M | -16.27M | -18.30M | -42.20M | -32.54M | -33.36M | -29.69M | -26.51M | -17.84M | -19.64M | -19.88M | -13.56M |
| Operating Income Ratio | -6,060.24% | 0.00% | 0.00% | 0.00% | 0.00% | -6,365.33% | 0.00% | -1,678.53% | -831.79% | -1,293.94% | -1,658.12% | -21,888.41% | -2,344.49% | -2,371.14% | -2,009.22% | -4,811.63% | -25,222.48% | -8,620.67% | -3,651.91% | -42,761.29% | -10,492.35% | 0.00% | -66,250.00% | -13,838.78% |
| Total Other Income/Expenses | -98.00K | 1.74M | 204.00K | 955.00K | 556.00K | 923.00K | 1.03M | 376.00K | -316.00K | -212.00K | 6.09M | -4.00K | 580.00K | 245.00K | -2.58M | -8.36M | 4.89M | 1.63M | 827.00K | 1.31M | -1.00K | 0.00 | 19.88M | 621.00K |
| Income Before Tax | -25.55M | -25.92M | -22.73M | -9.68M | -9.13M | -8.63M | -8.46M | -13.77M | -16.49M | -22.65M | -11.88M | -15.11M | -15.81M | -16.68M | -20.52M | -42.14M | -26.09M | -31.50M | -37.09M | -27.24M | -17.84M | 0.00 | 0.00 | -12.94M |
| Income Before Tax Ratio | -6,083.57% | 0.00% | 0.00% | 0.00% | 0.00% | -5,750.00% | 0.00% | -1,633.93% | -848.05% | -1,306.17% | -1,095.94% | -21,894.20% | -2,261.52% | -2,431.20% | -2,252.25% | -4,804.45% | -20,227.91% | -8,140.31% | -4,561.87% | -43,933.87% | -10,492.94% | 0.00% | 0.00% | -13,205.10% |
| Income Tax Expense | -3.00M | -4.72M | -3.85M | -1.24M | -1.30M | -1.34M | -993.00K | -1.98M | -2.14M | -3.24M | -1.67M | -1.35M | -565.00K | -657.00K | -948.00K | -1.75M | -2.04M | -2.25M | -274.00K | 13.08M | 620.00K | 19.45M | 19.51M | 0.00 |
| Net Income | -22.56M | -21.20M | -18.89M | -8.45M | -7.83M | -7.29M | -7.47M | -11.79M | -14.34M | -19.39M | -10.15M | -13.19M | -15.24M | -16.02M | -19.57M | -40.39M | -24.05M | -29.26M | -29.42M | -39.59M | -18.46M | -19.45M | -19.51M | -12.94M |
| Net Income Ratio | -5,370.24% | 0.00% | 0.00% | 0.00% | 0.00% | -4,858.67% | 0.00% | -1,398.70% | -737.76% | -1,118.05% | -936.62% | -19,110.14% | -2,180.69% | -2,335.42% | -2,148.19% | -4,605.02% | -18,645.74% | -7,560.21% | -3,618.20% | -63,851.61% | -10,857.06% | 0.00% | -65,040.00% | -13,205.10% |
| EPS | -26.75 | -32.23 | -31.74 | -34.86 | -143.88 | -12.05 | -19.58 | -68.85 | -105.72 | -211.93 | -160.75 | -440.40 | -509.10 | -711.22 | -1.48K | -3.32K | -2.03K | -3.67K | -7.42K | -5.35K | -2.10K | -4.91K | -4.92K | -3.27K |
| EPS Diluted | -26.75 | -32.23 | -31.74 | -34.86 | -143.88 | -12.05 | -19.58 | -68.85 | -105.72 | -211.93 | -160.75 | -440.40 | -509.10 | -711.22 | -1.48K | -3.32K | -2.03K | -3.67K | -7.42K | -5.35K | -2.10K | -4.21K | -4.22K | -2.80K |
| Weighted Avg Shares Out | 850.82K | 657.62K | 595.08K | 242.23K | 54.41K | 604.71K | 381.56K | 171.25K | 135.65K | 91.48K | 63.16K | 29.94K | 29.94K | 22.53K | 13.21K | 12.16K | 11.83K | 7.97K | 3.96K | 7.40K | 8.79K | 3.96K | 3.96K | 3.96K |
| Weighted Avg Shares Out (Dil) | 850.82K | 657.62K | 595.08K | 242.23K | 54.41K | 604.71K | 381.56K | 171.25K | 135.65K | 91.48K | 63.16K | 29.94K | 29.94K | 22.53K | 13.21K | 12.16K | 11.83K | 7.97K | 3.96K | 7.40K | 8.79K | 4.62K | 4.62K | 4.62K |
Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
BERKELEY HEIGHTS, N.J., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it has entered into a definitive...
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
- Patient Pharmacodynamic Data Show Decrease in CDKN2A, CDKN2B, and PRMT5 Protein Levels - - A Squamous Non-Small Cell Lung Cancer Patient with CDKN2B Deletion Achieved Marked Tumor Shrinkage after One Cycle - - Retrospective Analysis Identified CDKN2A, CDKN2B and/or...
Cyclacel Pharmaceuticals Announces Reverse Stock Split
BERKELEY HEIGHTS, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it will implement a 1-for-15 Reverse...
Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
BERKELEY HEIGHTS, N.J., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it received a notice from The Nasdaq...
Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q
BERKELEY HEIGHTS, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it received a notice of non-compliance...
Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q3 2023 Results Conference Call November 13, 2023 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - President, CEO Paul McBarron - EVP, Finance & COO Mark Kirschbaum - SVP, CMO Conference...
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
- Cyclacel Expects to Release Updated Phase 1/2 Clinical and Biomarker Data with Oral Fadraciclib and Provide Safety, Efficacy and Putative Mechanism Update for Oral Plogosertib -
Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results
BERKELEY HEIGHTS, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2023 financial results on Monday,...
Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results
BERKELEY HEIGHTS, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2023 financial results on Wednesday...
Cyclacel Pharmaceuticals Inc. (CYCC) Q1 2023 Earnings Call Transcript
Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC ) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - CEO Mark Kirschbaum - CMO Paul McBarron - CFO Conference Call Participants Ahu Demir -...
Source: https://incomestatements.info
Category: Stock Reports